Percipient Welcomes Karen O’Neal as Vice President
SOMERVILLE (April 8, 2015) – Percipient announced today that it has appointed Karen O’Neal as Vice President. Karen will play a leadership role and enhance our recognized excellence in Market Access strategy for biopharmaceutical and other life science companies. Percipient is playing an increasing role in value-based positioning of new therapies. In this context, Karen’s rich experience in contracting strategy and risk-sharing programs will enable us to deliver a higher level of strategic support in institutional and payer markets.
Click here to read more
Percipient welcomes Ken LaPensee as Vice President
SOMERVILLE (February 10, 2015) – Percipient announced today that it has appointed Ken LaPensee as Vice President. Ken will play a leadership role and enhance our recognized excellence in Market Access strategy for biopharmaceutical and other life science companies. Percipient is playing an increasing role in value-based positioning of new therapies and our clients are seeking greater alignment across global markets in doing so.
Click here to read more
A poster presentation “Perceived Benefits and Barriers of Payer-Manufacturer Post-Marketing Outcomes Study Collaborations”
Payer-manufacturer post-marketing outcomes research collaborations will become increasingly critical as competition in the pharmaceutical marketplace increases and recent US healthcare reform moves forward. The study unveiled benefits and barriers of collaboration perceived by payers and manufacturers. In addition, important criteria for payers in selecting a pharmaceutical partner and key factors for manufacturers for a successful partnership was discussed.
Percipient hosted a webinar on our presentation at AMCP, “Payer Evidence Requirements for New Drugs: Trends and Impact”
The free webinar covered original research first presented on April 3rd at AMCP. The session explored the evidence that US payers are requesting and receiving for new products at launch, how evidence is used during drug review, how current evidence can be improved, and how the use and availability of evidence may change over the next 5 years.
Percipient presented “Payer Evidence Requirements for New Drugs: Trends and Impact” at the AMCP Annual Meeting
In the United States, new drugs are approved based on evidence of clinical efficacy and safety. Although that evidence might suffice for regulatory approval, payers increasingly are demanding more rigorous data that also demonstrate economic value. Pharmaceutical manufacturers are responding by building capabilities and processes for incorporating health outcomes measures into clinical development programs. Percipient presented the result of original research conducted with payer decision makers and manufacturers, which illuminated key issues including payer evidence requirements in demonstrating a drug’s value and manufacturer involvement in providing useful evidence to payers to justify access and reimbursement at the time of launch.
Click here for the presentation coverage on AJMC.com
Should pharma companies try to delight customers?
Sam Malik, Managing Partner at Percipient, participated in the panel discussion at the 10th annual SAS Health Care and Life Sciences Executive Conference.
Click here for the panel discussion coverage